Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia

Inclusion Criteria: * Males or non-pregnant females (who must agree to use barrier methods of contraception during the study therapy period, women of childbearing age must have a negative urine pregnancy or serum test at baseline). * Subjects who are 18 years of age or older * Subjects with at least one positive blood culture isolation of Candida species from a specimen drawn within 96 hours prior to study entry. * Subjects who have clinical evidence of infection AT SOME TIME WITHIN 96 HOURS PRIOR TO ENROLLMENT, including AT LEAST ONE of the following: * Temperature \>37.8 ˚C on 2 occasions at least 4 hours apart or one measurement \> 38.2 ˚C * Systolic blood pressure \<90 or a \>30 mmHg decrease in systolic BP from the subject's normal baseline. * Signs of inflammation (swelling, heat, erythema, purulent drainage) from a site infected with Candida (eg, joint, skin, eye, bone, esophagus) * Radiologic findings of invasive candidiasis * Subject or their legal representative must sign a written informed consent form. Exclusion Criteria: * Subjects with a history of allergy or intolerance to echinocandins or IFNgamma * Subjects with a history of documented epileptic seizures * Subjects with severe renal impairment (creatinine clearance less than 30/mL/min) * Subjects with severe liver failure (impaired synthesis of proteins such as coagulation factors manifested by increased prothrombin time) * Subjects with an absolute neutrophil count of less than 500/mm3 at study entry * Women who are pregnant or lactating * Subjects who are unlikely to survive more than 24 hours * Subjects who have failed previous systemic antifungal therapy for the Candida spp. infection which is being studied. * Subjects who have received more than 48 hours of systemic antifungal therapy for the current episode, within 96 hours prior to study entry